Currently, the clinical treatment of DKD mainly includes angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and sodium-dependent glucose transporter 2 (SGLT2) inhibitors [26,27]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.